A Phase 2 interventional study of SPC 1001 Mid2 and SPC 2002 in Hypertension, Essential, Cardiovascular Diseases and Cardiology, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-14.
Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Essential Hypertension with a site in Korea, Republic of — 11 open to participants now, 13 under way, 4 of them phase 3. Essential Hypertension · Korea, Republic of.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, this one is the 33rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 11 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 90th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →11 of the 99 studies in Essential Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of, Indonesia
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 252 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 190 across the 86 interventional studies, 3,250 across the 13 observational. Of the 78 that completed or were terminated, 7 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 99 have an industry lead sponsor. The 10 most frequent:
Shin Poong Pharmaceutical Co. Ltd. is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Shin Poong Pharmaceutical Co. Ltd. has 3 studies filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Essential Hypertension with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07373613Boryung Pharmaceutical Co., LtdA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | 2027-02-01 |
| NCT06282549Yuhan CorporationStudy to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Essential Hypertension with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: SPC 1001 Mid2
Drug: SPC 1001 Mid2 · Drug: SPC 2002
Drug: SPC 1001 Mid2 · Drug: SPC 2003
Drug: SPC 1001 Mid2 · Drug: SPC 2004
low-dose combination therapy
low-dose combination therapy
low-dose combination therapy
low-dose combination therapy
The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8.
Time frame: Change from Baseline in MSSBP at Week 8
Plan to share: Yes — It is planned to be publicly available in the form of a future journal submission.
Supporting information: Study protocol
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.
Of 16 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shin Poong Pharmaceutical Co. Ltd. →